Capital Fund Management (CFM)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capital Fund Management (CFM)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.4M	Buy	230,200 +1,100	+0.5%	+$137K	0.13%	186
2025 Q4	$27.9M	Sell	229,100 -299,600	-57%	-$34.4M	0.08%	346
2025 Q3	$53M	Sell	528,700 -255,300	-33%	-$23M	0.14%	178
2025 Q2	$65M	Sell	784,000 -208,500	-21%	-$16.6M	0.18%	149
2025 Q1	$80.5M	Buy	992,500 +320,900	+48%	+$28.7M	0.23%	109
2024 Q4	$60.5M	Buy	671,600 +321,400	+92%	+$31.1M	0.15%	190
2024 Q3	$34.6M	Sell	350,200 -539,300	-61%	-$53M	0.09%	282
2024 Q2	$82.5M	Sell	889,500 -142,500	-14%	-$12.8M	0.24%	105
2024 Q1	$97.9M	Buy	1,032,000 +85,900	+9%	+$7.97M	0.28%	71
2023 Q4	$84.5M	Buy	946,100 +762,400	+415%	+$56.6M	0.23%	95
2023 Q3	$13.4M	Sell	183,700 -20,300	-10%	-$1.62M	0.05%	494
2023 Q2	$17M	Buy	204,000 +67,900	+50%	+$5.68M	0.07%	384
2023 Q1	$10.4M	Sell	136,100 -66,200	-33%	-$5.49M	0.05%	482
2022 Q4	$16.8M	Sell	202,300 -121,100	-37%	-$9.8M	0.11%	248
2022 Q3	$25.7M	Sell	323,400 -61,800	-16%	-$5.21M	0.2%	131
2022 Q2	$28.6M	Sell	385,200 -139,800	-27%	-$10.5M	0.26%	84
2022 Q1	$47.2M	Buy	525,000 +477,500	+1,005%	+$44.1M	0.39%	31
2021 Q4	$5.32M	Sell	47,500 -9,700	-17%	-$1.17M	0.04%	614
2021 Q3	$7.19M	Sell	57,200 -19,300	-25%	-$2.49M	0.05%	466
2021 Q2	$10.4M	Sell	76,500 -35,400	-32%	-$4.65M	0.08%	328
2021 Q1	$15.2M	Buy	111,900 +82,300	+278%	+$12.3M	0.17%	163
2020 Q4	$4.17M	Sell	29,600 -89,700	-75%	-$11.5M	0.04%	530
2020 Q3	$13.3M	Buy	119,300 +71,600	+150%	+$8.03M	0.16%	158
2020 Q2	$5.34M	Buy	47,700 +20,300	+74%	+$2M	0.08%	293
2020 Q1	$2.12M	Sell	27,400 -5,300	-16%	-$469K	0.03%	511
2019 Q4	$3.11M	Buy	32,700 +27,100	+484%	+$2.34M	0.02%	696
2019 Q3	$427K	Sell	5,600 -5,700	-50%	-$474K	﹤0.01%	1311
2019 Q2	$991K	Sell	11,300 -12,600	-53%	-$1.07M	0.01%	1020
2019 Q1	$2.16M	Sell	23,900 -149,500	-86%	-$12.7M	0.02%	778
2018 Q4	$12.4M	Buy	+173,400	New	+$14M	0.11%	249
2018 Q2	–	Sell	-12,800	Closed	-$1.12M	–	2310
2018 Q1	$1.12M	Sell	12,800 -51,100	-80%	-$4.67M	0.01%	1196
2017 Q4	$5.42M	Sell	63,900 -18,800	-23%	-$1.57M	0.03%	649
2017 Q3	$7.16M	Buy	82,700 +58,300	+239%	+$4.67M	0.05%	427
2017 Q2	$1.88M	Buy	+24,400	New	+$1.73M	0.02%	728
2017 Q1	–	Sell	-64,400	Closed	-$3.81M	–	1873
2016 Q4	$3.81M	Buy	64,400 +41,400	+180%	+$2.56M	0.03%	582
2016 Q3	$1.52M	Sell	23,000 -41,500	-64%	-$2.57M	0.01%	842
2016 Q2	$3.49M	Sell	64,500 -340,300	-84%	-$18.6M	0.03%	545
2016 Q1	$20.9M	Buy	404,800 +263,400	+186%	+$13.7M	0.2%	125
2015 Q4	$9.91M	Sell	141,400 -47,800	-25%	-$3.26M	0.1%	268
2015 Q3	$11.8M	Buy	189,200 +71,300	+60%	+$5.62M	0.13%	202
2015 Q2	$9.91M	Buy	117,900 +86,100	+271%	+$6.7M	0.13%	219
2015 Q1	$2.39M	Buy	+31,800	New	+$2.22M	0.03%	539

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capital Fund Management (CFM)'s XBI Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2025, closing a stake of 19,838 shares — an estimated $1.79M sold.

Capital Fund Management (CFM) first reported a position in XBI in Q2 2014 and held it in 30 quarters. The position peaked at $48.1M in Q3 2023. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

Capital Fund Management (CFM) reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 19,838 State Street SPDR S&P Biotech ETF shares in Q3 2025, an estimated $1.79M.
Capital Fund Management (CFM) first reported a position in State Street SPDR S&P Biotech ETF in Q2 2014 and held it in 30 quarters.
Capital Fund Management (CFM)'s State Street SPDR S&P Biotech ETF position peaked at $48.1M in Q3 2023.
656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.